Regenxbio Reports 'Positive' Interim Data in Duchenne Trial

MT Newswires Live

03/12

Regenxbio (RGNX) said Wednesday new interim results of its gene therapy RGX-202 study in Duchenne muscular dystrophy showed evidence of "positively" changing disease trajectory.

The company said favorable safety profile continued with no serious adverse events or adverse events of special interest observed in the phase I/II study.

The firm also said it expects pivotal topline data in Q2 and plans to seek a pre-Biologics License Application meeting with the US Food and Drug Administration in mid-2026.

Shares were down more than 6% in midday trading.

Price: 9.22, Change: -0.68, Percent Change: -6.87

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2618921027"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2618921027\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2618921027?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 00:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618921027","market":"sg","top_or_hot":-1,"title":"Regenxbio Reports 'Positive' Interim Data in Duchenne Trial","media":"MT Newswires Live","content":"<html><body><p> Regenxbio (RGNX) said Wednesday new interim results of its gene therapy RGX-202 study in Duchenne muscular dystrophy showed evidence of \"positively\" changing disease trajectory.</p><p>The company said favorable safety profile continued with no serious adverse events or adverse events of special interest observed in the phase I/II study.</p><p>The firm also said it expects pivotal topline data in Q2 and plans to seek a pre-Biologics License Application meeting with the US Food and Drug Administration in mid-2026.</p><p>Shares were down more than 6% in midday trading.</p><p>Price: 9.22, Change: -0.68, Percent Change: -6.87</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regenxbio Reports 'Positive' Interim Data in Duchenne Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegenxbio Reports 'Positive' Interim Data in Duchenne Trial\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-03-12 00:37</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Regenxbio (RGNX) said Wednesday new interim results of its gene therapy RGX-202 study in Duchenne muscular dystrophy showed evidence of \"positively\" changing disease trajectory.</p><p>The company said favorable safety profile continued with no serious adverse events or adverse events of special interest observed in the phase I/II study.</p><p>The firm also said it expects pivotal topline data in Q2 and plans to seek a pre-Biologics License Application meeting with the US Food and Drug Administration in mid-2026.</p><p>Shares were down more than 6% in midday trading.</p><p>Price: 9.22, Change: -0.68, Percent Change: -6.87</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4563","symbol_name":"昨日強勢股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618921027","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618921027","pubTimestamp":1773247037,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regenxbio  said Wednesday new interim results of its gene therapy RGX-202 study in Duchenne muscular dystrophy showed evidence of \"positively\" changing disease trajectory.The company said favorable safety profile continued with no serious adverse events or adverse events of special interest observed in the phase I/II study.The firm also said it expects pivotal topline data in Q2 and plans to seek a pre-Biologics License Application meeting with the US Food and Drug Administration in mid-2026.Shares were down more than 6% in midday trading.Price: 9.22, Change: -0.68, Percent Change: -6.87","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4563":"昨日强势股","BK4139":"生物科技","RGNX":"Regenxbio Inc","BK4505":"高瓴资本持仓"},"translate_title":"Regenxbio报告杜兴试验的“积极”中期数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RGNX":1.5},"content_text":"Regenxbio (RGNX) said Wednesday new interim results of its gene therapy RGX-202 study in Duchenne muscular dystrophy showed evidence of \"positively\" changing disease trajectory.The company said favorable safety profile continued with no serious adverse events or adverse events of special interest observed in the phase I/II study.The firm also said it expects pivotal topline data in Q2 and plans to seek a pre-Biologics License Application meeting with the US Food and Drug Administration in mid-2026.Shares were down more than 6% in midday trading.Price: 9.22, Change: -0.68, Percent Change: -6.87","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}